ArticleJournal of virology1996
Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 124 citations in OpenAlex.
- Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023Review
- Adenoviral vector-based strategies against infectious disease and cancer.Human vaccines & immunotherapeutics · 2016Review
- Adenoviral producer cells.Viruses · 2010Article
- New insights on adenovirus as vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
- Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?Gene therapy · 2007Article
- Chimpanzee-origin adenovirus vectors as vaccine carriers.Gene therapy · 2006Article
- Robust functional gene validation by adenoviral vectors: one-step Escherichia coli-derived recombinant adenoviral genome construction.Gene therapy · 2004Article
- Adenoviruses as vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2004Review
- Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.Gene therapy · 2004Article
- Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor.Journal of neuro-oncology · 2002Article
- Degenerated pIX-IVa2 adenoviral vector sequences lowers reacquisition of the E1 genes during virus amplification in 293 cells.Gene therapy · 2001Article
- Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications.Journal of virology · 2001Article
- Adenovirus vector-directed expression of the neurotrophin-3 receptor (TrkC) in mouse astrocytes.Journal of neurovirology · 2001Article
- Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.Journal of virology · 2000Article
- Production of first generation adenovirus vectors: a review.Gene therapy · 2000Review
- Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes.Gene therapy · 2000Article
- An improved anion-exchange HPLC method for the detection and purification of adenoviral particles.Gene therapy · 2000Article
- Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer.Journal of virology · 2000Article
- Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.Journal of virology · 2000Article
- Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.Journal of virology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transgene expression after the administration of recombinant adenovirus with E1 deleted is constantly transient. It is admitted that E1A-substituting activities of cellular or viral origin allow viral antigen synthesis and trigger cytotoxic lymphocyte-mediated clearance of the recipient cells. Our approach to solving this problem relies on the additional deletion of the E4 region from the vector backbone as this region upregulates viral gene expression at both transcriptional and posttranscriptional levels. As a prerequisite to the construction of E1 E4 doubly defective adenoviruses, we investigated the possibility of transcomplementing both functions within a single cell. In particular, the distal ORF6+ORF7 segment from the E4 locus of adenovirus type 5 was cloned under the control of the dexamethasone-inducible mouse mammary tumor virus long terminal repeat. Following transfection into 293 cells, clone IGRP2 was retained and characterized as it can rescue the growth defect of all E1+ E4- adenoviral deletants tested. DNA and RNA analysis experiments verified that the mouse mammary tumor virus promoter drives the expression of the ORF6+ORF7 unit and permits its bona fide alternative splicing, generating ORF6/7 mRNA in addition to the ORF6-expressing primary transcript. Importantly, IGRP2 cells sustain cell confluence for a period longer than that of 293 parental cells and allow the plaque purification of E1- or E4- defective viruses. The dual expression of E1 and E4 regulatory genes within IGRP2 cells is demonstrated by the construction, plaque purification, and helper-free propagation of recombinant lacZ-encoding doubly defective adenoviruses harboring different E4 deletions. In addition, the emergence, if any, of replicative particles during viral propagation in this novel packaging cell line will be drastically impaired as only a limited segment of E4 has been integrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.